非转移性前列腺癌短程雄激素剥夺治疗与放疗的顺序安排(SANDSTORM):12项随机试验的汇总分析
该汇总分析纳入12项随机试验的7409例接受短期ADT(4-6个月)联合放疗的局限期前列腺癌患者,比较新辅助/同步与同步/辅助ADT顺序对结局的影响。在仅前列腺放疗(PORT)患者中,同步/辅助ADT较新辅助/同步显著改善无转移生存、远处转移、前列腺癌特异性死亡和总生存;而在全盆腔放疗(WPRT)患者中除远处转移更差外无显著差异,ADT顺序与放疗野大小存在显著交互作用。
要点
- PORT患者中,同步/辅助ADT较新辅助/同步显著改善无转移生存(10年获益8.0%,HR 0.65)。
- PORT患者中,同步/辅助ADT较新辅助/同步显著改善OS(HR 0.69,95%CI 0.57-0.83)。
- WPRT患者中,同步/辅助ADT较新辅助/同步远处转移更差(HR 1.57),其余终点无显著差异。
核心结论
- ADT顺序对临床结局有显著影响,且与放疗野大小存在显著交互作用。
- 在PORT联合短期ADT时,同步/辅助ADT应作为标准治疗。
研究设计与样本
- 研究为基于12项随机试验个体患者数据的汇总分析,数据来自前列腺癌随机试验荟萃分析联盟。
- 纳入接受新辅助/同步或同步/辅助短期ADT(4-6个月)联合放疗的局限期前列腺癌患者。
- 共纳入7409例患者,其中新辅助/同步6325例,同步/辅助1084例。
- 采用逆概率治疗加权(IPTW),倾向评分基于年龄、初始前列腺特异性抗原、Gleason评分、T分期、放疗剂量和试验入组中位年份。
- 中位随访10.2年(四分位距7.2-14.9年)。
主要发现
- ADT顺序与放疗野大小对所有终点均存在显著交互作用(所有P交互<0.02),但OS除外。
- PORT患者(n=4355)中,同步/辅助ADT较新辅助/同步ADT改善无转移生存(10年获益8.0%,HR 0.65,95%CI 0.54-0.79,P<0.0001)。
- PORT患者中,同步/辅助ADT较新辅助/同步ADT改善远处转移(亚分布HR 0.52,95%CI 0.33-0.82,P=0.0046)。
- PORT患者中,同步/辅助ADT较新辅助/同步ADT改善前列腺癌特异性死亡(亚分布HR 0.30,95%CI 0.16-0.54,P<0.0001)和OS(HR 0.69,95%CI 0.57-0.83,P=0.0001)。
- WPRT患者(n=3049)中,除同步/辅助ADT远处转移更差(HR 1.57,95%CI 1.20-2.05,P=0.0009)外,ADT顺序对其他终点无显著差异。
关键数值与推荐
- PORT患者中,同步/辅助ADT较新辅助/同步ADT的10年无转移生存绝对获益为8.0%。
- PORT患者中,同步/辅助ADT较新辅助/同步ADT的远处转移亚分布HR为0.52(95%CI 0.33-0.82,P=0.0046)。
- PORT患者中,同步/辅助ADT较新辅助/同步ADT的前列腺癌特异性死亡亚分布HR为0.30(95%CI 0.16-0.54,P<0.0001)。
- WPRT患者中,同步/辅助ADT较新辅助/同步ADT的远处转移HR为1.57(95%CI 1.20-2.05,P=0.0009)。
临床怎么用
- 在PORT联合短期ADT时,同步/辅助ADT应作为标准治疗。
- WPRT患者中,ADT顺序除同步/辅助ADT远处转移更差外,其他终点无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT). MATERIALS AND METHODS: Individual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate consortium. Inverse probability of treatment weighting (IPTW) was performed with propensity scores derived from age, initial prostate-specific antigen, Gleason score, T stage, RT dose, and mid-trial enrollment year. Metastasis-free survival (primary end point) and overall survival (OS) were assessed by IPTW-adjusted Cox regression models, analyzed independently for men receiving PORT versus WPRT. IPTW-adjusted Fine and Gray competing risk models were built to evaluate distant metastasis (DM) and prostate cancer-specific mortality. RESULTS: Overall, 7,409 patients were included (6,325 neoadjuvant/concurrent and 1,084 concurrent/adjuvant) with a median follow-up of 10.2 years (interquartile range, 7.2-14.9 years). A significant interaction between ADT sequencing and RT field size was observed for all end points (P interaction < .02 for all) except OS. With PORT (n = 4,355), compared with neoadjuvant/concurrent ADT, concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, hazard ratio [HR], 0.65; 95% CI, 0.54 to 0.79; P < .0001), DM (subdistribution HR, 0.52; 95% CI, 0.33 to 0.82; P = .0046), prostate cancer-specific mortality (subdistribution HR, 0.30; 95% CI, 0.16 to 0.54; P < .0001), and OS (HR, 0.69; 95% CI, 0.57 to 0.83; P = .0001). However, in patients receiving WPRT (n = 3,049), no significant difference in any end point was observed in regard to ADT sequencing except for worse DM (HR, 1.57; 95% CI, 1.20 to 2.05; P = .0009) with concurrent/adjuvant ADT. CONCLUSION: ADT sequencing exhibits a significant impact on clinical outcomes with a significant interaction with field size. Concurrent/adjuvant ADT should be the standard of care where short-term ADT is indicated in combination with PORT.
引用
- Ma TM, Sun Y, Malone S, et al. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. J Clin Oncol. 2022. PMID: 36269935. doi:10.1200/JCO.22.00970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。